German biotech today announced that the US Food and Drug Administration (FDA) has granted fast track designation to BNT113, ...

MSK radiation oncologist Dr. Nadeem Riaz and colleagues discovered that bacteria inside tumors can undermine the effects of immunotherapy. In cancer research, failure can lead to an important ...

Studies published in Nature Cancer reveal how bacterial presence in head and neck cancers affects treatment response, potentially opening doors for targeted antibiotic therapies.

Bacteria in head and neck tumor stimulate immunotherapy resistance by attracting immune cells and creating a shield. Targeting microbiome is a key.

HPV status, particularly combined p16 and HPV positivity, is vital for patient selection in de-escalation strategies for ...

Esophageal cancer occurring in patients with head and neck squamous cell carcinoma (HNSCC) represents a critical clinical challenge, as these secondary tumours notably worsen patient prognosis. Owing ...

HealthDay News — The rate of early termination or withdrawal in head and neck squamous cell carcinoma (HNSCC) clinical trials (CTs) has increased since 2000, with strategic decisions and poor ...

Panelists discuss how recurrent metastatic head and neck squamous cell carcinoma (HNSCC) manifests through symptoms such as persistent sore throat and neck lumps, with risk factors including tobacco ...